-
1
-
-
77951089891
-
-
International Diabetes Federation. 5th Edition 2012 Update: New Estimates for 2012 of Diabetes Prevalence Mortality, and Healthcare Expenditure
-
International Diabetes Federation. IDF Diabetes Atlas 5th Edition 2012 Update: New Estimates for 2012 of Diabetes Prevalence, Mortality, and Healthcare Expenditure. 2012
-
(2012)
IDF Diabetes Atlas
-
-
-
2
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the american diabetes association (ada and the european association for the study of diabetes (easd
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
-
(2012)
Diabetes Care
, vol.35
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
3
-
-
84857226676
-
DPP-4 inhibition and islet function
-
Ahren B. DPP-4 inhibition and islet function. J Diabetes Investig 2012;3:3-10
-
(2012)
J Diabetes Investig
, vol.3
, pp. 3-10
-
-
Ahren, B.1
-
4
-
-
84878360808
-
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas
-
Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30
-
(2013)
J Diabetes Investig
, vol.4
, pp. 108-130
-
-
Seino, Y.1
Yabe, D.2
-
5
-
-
84871651233
-
Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
-
Kubota A, Maeda H, Kanamori A, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig 2012;3:503-9
-
(2012)
J Diabetes Investig
, vol.3
, pp. 503-509
-
-
Kubota, A.1
Maeda, H.2
Kanamori, A.3
-
6
-
-
84904597331
-
Factors influencing durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea
-
published online 11 February 2014 doi:10.1111/jdi.12182
-
Kubota A, Yabe D, Kanamori A, et al. Factors influencing durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. J Diabetes Investig 2014: Published online 11 February 2014, doi:10.1111/jdi.12182
-
(2014)
J Diabetes Investig
-
-
Kubota, A.1
Yabe, D.2
Kanamori, A.3
-
7
-
-
84859739099
-
Expression of Na-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences
-
Sabolic I, Vrhovac I, Eror DB, et al. Expression of Na-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 2012;302:C1174-88
-
(2012)
Am J Physiol Cell Physiol
, vol.302
-
-
Sabolic, I.1
Vrhovac, I.2
Eror, D.B.3
-
8
-
-
84865400266
-
Role of sodium-glucose transporters in glucose uptake of the intestine and kidney
-
Harada N, Inagaki N. Role of sodium-glucose transporters in glucose uptake of the intestine and kidney. J Diabetes Investig 2012;3:352-3
-
(2012)
J Diabetes Investig
, vol.3
, pp. 352-35353
-
-
Harada, N.1
Inagaki, N.2
-
9
-
-
67349189212
-
Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications
-
Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7
-
(2009)
Kidney Int
, vol.75
, pp. 1272-1277
-
-
Bakris, G.L.1
Fonseca, V.A.2
Sharma, K.3
-
10
-
-
79952404360
-
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
-
Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011;60:890-8
-
(2011)
Diabetes
, vol.60
, pp. 890-898
-
-
Jurczak, M.J.1
Lee, H.Y.2
Birkenfeld, A.L.3
-
11
-
-
78651406659
-
SGLT2 mediates glucose reabsorption in the early proximal tubule
-
Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011;22:104-12
-
(2011)
J Am Soc Nephrol
, vol.22
, pp. 104-112
-
-
Vallon, V.1
Platt, K.A.2
Cunard, R.3
-
12
-
-
84872400230
-
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
-
Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013;304:F156-67
-
(2013)
Am J Physiol Renal Physiol
, vol.304
-
-
Vallon, V.1
Rose, M.2
Gerasimova, M.3
-
13
-
-
64749089393
-
Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus
-
Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008;14:782-90
-
(2008)
Endocr Pract
, vol.14
, pp. 782-790
-
-
Abdul-Ghani, M.A.1
DeFronzo, R.A.2
-
14
-
-
83655193529
-
The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia
-
DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 5-14
-
-
DeFronzo, R.A.1
Davidson, J.A.2
Del Prato, S.3
-
15
-
-
75149196250
-
Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus
-
Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 34-42
-
-
Nair, S.1
Wilding, J.P.2
-
16
-
-
84864283226
-
SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects
-
Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502
-
(2012)
Nat Rev Endocrinol
, vol.8
, pp. 495-502
-
-
Ferrannini, E.1
Solini, A.2
-
17
-
-
77951143723
-
1S-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl] -1-Thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment
-
Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (1S)-1,5-Anhydro-1-[5-(4- ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-Thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010;53:3247-61
-
(2010)
J Med Chem
, vol.53
, pp. 3247-3261
-
-
Kakinuma, H.1
Oi, T.2
Hashimoto-Tsuchiya, Y.3
-
18
-
-
79961228970
-
TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity
-
Yamamoto K, Uchida S, Kitano K, et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 2011;164:181-91
-
(2011)
Br J Pharmacol
, vol.164
, pp. 181-191
-
-
Yamamoto, K.1
Uchida, S.2
Kitano, K.3
-
19
-
-
84898890575
-
Safety, Pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: A randomized, single-blind, placebo-controlled trial
-
published online 18 February 2014 doi:10.1007/s12325-014-0102-3
-
Sasaki T, Seino Y, Fukatsu A, et al. Safety, Pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: A randomized, single-blind, placebo-controlled trial. Adv Ther 2014: Published online 18 February 2014, doi:10.1007/s12325-014-0102-3
-
(2014)
Adv Ther
-
-
Sasaki, T.1
Seino, Y.2
Fukatsu, A.3
-
20
-
-
84903569376
-
Ts-071 a novel potent and highly selective renal sodium-glucose co-Transporter 2 (sglt2) inhibitor increases urinary glucose excretion and reduces plasma glucose levels in japanese patients with type 2 diabetes mellitus
-
12-16 September 2011. Lisbon, Portugal
-
Sasaki T, Seino Y, Fukatsu A, et al. TS-071, a novel potent and highly selective renal sodium-glucose co-Transporter 2 (SGLT2) inhibitor, increases urinary glucose excretion and reduces plasma glucose levels in Japanese patients with type 2 diabetes mellitus. 47th European Association for the Study of Diabetes (EASD) Annual Meeting, 12-16 September 2011. Lisbon, Portugal, 2011
-
(2011)
47th European Association For The Study Of Diabetes (EASD) Annual Meeting
-
-
Sasaki, T.1
Seino, Y.2
Fukatsu, A.3
-
21
-
-
84861993148
-
Risk factors for type 2 diabetes: Lessons learned from japanese americans in seattle
-
Fujimoto WY, Boyko EJ, Hayashi T, et al. Risk factors for type 2 diabetes: Lessons learned from Japanese Americans in Seattle. J Diabetes Investig 2012;3:212-24
-
(2012)
J Diabetes Investig
, vol.3
, pp. 212-224
-
-
Fujimoto, W.Y.1
Boyko, E.J.2
Hayashi, T.3
-
22
-
-
0036138569
-
Report of the committee on the classification and diagnostic criteria of diabetes mellitus
-
10.1016/S0168-8227(01)00365-5, PII S0168822701003655
-
Kuzuya T, Nakagawa S, Satoh J, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetes Res Clin Pract 2002;55:65-85 (Pubitemid 34036538
-
(2002)
Diabetes Research and Clinical Practice
, vol.55
, Issue.1
, pp. 65-85
-
-
Kuzuya, T.1
Nakagawa, S.2
Satoh, J.3
Kanazawa, Y.4
Iwamoto, Y.5
Kobayashi, M.6
Nanjo, K.7
Sasaki, A.8
Seino, Y.9
Ito, C.10
Shima, K.11
Nonaka, K.12
Kadowaki, T.13
-
23
-
-
84857217561
-
International clinical harmonization of glycated hemoglobin in japan: From japan diabetes society to national glycohemoglobin standardization program values
-
Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 2012;3:8-10
-
(2012)
Diabetol Int
, vol.3
, pp. 8-10
-
-
Kashiwagi, A.1
Kasuga, M.2
Araki, E.3
-
24
-
-
65349196064
-
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes
-
List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
-
(2009)
Diabetes Care
, vol.32
, pp. 650-657
-
-
List, J.F.1
Woo, V.2
Morales, E.3
-
25
-
-
84865479822
-
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans
-
Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;61:2199-204
-
(2012)
Diabetes
, vol.61
, pp. 2199-2204
-
-
Liu, J.J.1
Lee, T.2
DeFronzo, R.A.3
-
26
-
-
84863610946
-
Effect of canagliflozin, a sodium glucose co-Transporter 2 (sglt2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study
-
Nicolle LE, Capuano G, Ways K, et al. Effect of canagliflozin, a sodium glucose co-Transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012;28:1167-71
-
(2012)
Curr Med Res Opin
, vol.28
, pp. 1167-1171
-
-
Nicolle, L.E.1
Capuano, G.2
Ways, K.3
-
27
-
-
84863617006
-
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-Transporter 2 inhibitor
-
Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-Transporter 2 inhibitor. Curr Med Res Opin 2012;28:1173-8.
-
(2012)
Curr Med Res Opin
, vol.28
, pp. 1173-1178
-
-
Nyirjesy, P.1
Zhao, Y.2
Ways, K.3
|